Tumour macrophages as potential targets of bisphosphonates

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Rogers, Thea L ^a   Holen, Ingunn ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Anti tumour effect; Bisphosphonates; Macrophages; Mevalonate pathway; Tumour microenvironment; Tumour associated macrophages; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM PHOSPHATE; CLODRONIC ACID; COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR; ETIDRONIC ACID; GELATINASE A; GELATINASE B; IBANDRONIC ACID; INTERLEUKIN 1; LIPOSOME; MATRILYSIN; MONOCYTE CHEMOTACTIC PROTEIN 1 INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PLATELET DERIVED GROWTH FACTOR; RISEDRONIC ACID; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE DISEASE; BONE METASTASIS; BONE PAIN; BREAST CANCER; BREAST CARCINOMA; BREAST TUMOR; CANCER INDUCED BONE DISEASE; CANCER INVASION; CANCER SURVIVAL; CELL ADHESION; CELL INFILTRATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; EXTRACELLULAR MATRIX; HUMAN; HYPERCALCEMIA; IMMUNOSTIMULATION; LIVER CANCER; LUNG CANCER; LUNG METASTASIS; MELANOMA; MESOTHELIOMA; METABOLIC BONE DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE METASTASIS; NANOENCAPSULATION; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; OVERALL SURVIVAL; PAGET BONE DISEASE; PATHOLOGIC FRACTURE; PLASMA HALF LIFE; PROGNOSIS; PROSTATE CANCER; PROTEIN PRENYLATION; REVIEW; RHABDOMYOSARCOMA; SOLID TUMOR; TERATOCARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UTERINE CERVIX CARCINOMA; ANIMAL; DRUG EFFECT; MACROPHAGE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DIPHOSPHONATES; HUMANS; MACROPHAGES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 80054075147     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-177     Document Type: Review

References (98)

1. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA, . ICBP Module 1 Working Group Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011, 377(9760):127-38. 10.1016/S0140-6736(10)62231-3, 3018568, 21183212, ICBP Module 1 Working Group.
2. Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res 2010, 12(6):214. 10.1186/bcr2769, 3046431, 21176176.
3. Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 2009, 1796(1):11-8.
4. Coffelt SB, Lewis CE, Naldini L, Brown JM, Ferrara N, De Palma M. Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol 2010, 176(4):1564-76. 10.2353/ajpath.2010.090786, 2843445, 20167863.
5. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008, 66(1):1-9. 10.1016/j.critrevonc.2007.07.004, 17913510.
6. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66(2):605-12. 10.1158/0008-5472.CAN-05-4005, 16423985.
7. Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis CE. Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood 2009, 113(14):3139-46. 10.1182/blood-2008-12-172825, 2869029, 19171876.
8. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006, 42(6):717-27. 10.1016/j.ejca.2006.01.003, 16520032.
9. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9(4):239-52. 10.1038/nrc2618, 19279573.
10. Y LE. Macrophages Regulate the Angiogenic Switch in a Mouse Model of Breast Cancer. Cancer Res 2006, 66(23):11238-46. 10.1158/0008-5472.CAN-06-1278, 17114237.
11. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001, 193(6):727-40. 10.1084/jem.193.6.727, 2193412, 11257139.
12. Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol 2000, 192(2):150-8. 10.1002/1096-9896(2000)9999:9999<::AID-PATH687>3.0.CO;2-G, 11004690.
13. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000, 6(8):3282-9.
14. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 2002, 7(2):177-89. 10.1023/A:1020304003704, 12463738.
15. Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 2004, 90(11):2053-8. 10.1038/sj.bjc.6601705, 2410285, 15164120.
16. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006, 66(11):5527-36. 10.1158/0008-5472.CAN-05-4128, 16740684.
17. Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 2006, 80(6):1183-96. 10.1189/jlb.0905495, 16997855.
18. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002, 196(3):254-65. 10.1002/path.1027, 11857487.
19. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996, 56(20):4625-9.
20. Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 2009, 8(7):1761-71. 10.1158/1535-7163.MCT-09-0280, 19567820.
21. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007, 67(23):11438-46. 10.1158/0008-5472.CAN-07-1882, 2646404, 18056472.
22. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004, 104(8):2224-34. 10.1182/blood-2004-03-1109, 15231578.
23. Leek RD, Talks KL, Pezzella F, Turley H, Campo L, Brown NS, et al. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res 2002, 62(5):1326-9.
24. El-Rouby DH. Association of macrophages with angiogenesis in oral verrucous and squamous cell carcinomas. J Oral Pathol Med 2010, 39(7):559-64.
25. Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer. United States 2000, 85(2):182-8.
26. al-Sarireh B, Eremin O. Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth. J R Coll Surg Edinb 2000, 45(1):1-16.
27. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 2005, 14(2):425-31.
28. Komanduri KC, Tomes DJ, Gabius HJ, Joshi SS. Macrophage-like-cell-induced growth regulation of lymphoma cells. Oncology 1995, 52(3):196-201. 10.1159/000227457, 7715903.
29. Hewlett G, Opitz HG, Flad HD, Schlumberger HD. Macrophages/monocytes require cell-to-cell contact in order to regulate the growth of a murine lymphoma cell line. J Immunol 1979, 123(5):2265-9.
30. Plytycz B, Pedersen A, Bogwald J, Seljelid R. In vitro interactions of murine peritoneal macrophages and sarcoma cells. I. Promotion of tumor cells proliferation by macrophages. Virchows Arch B Cell Pathol Incl Mol Pathol 1986, 50(3):285-92.
31. Richter G, Kruger-Krasagakes S, Hein G, Huls C, Schmitt E, Diamantstein T, et al. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res 1993, 53(18):4134-7.
32. Komohara Y, Takemura K, Lei XF, Sakashita N, Harada M, Suzuki H, et al. Delayed growth of EL4 lymphoma in SR-A-deficient mice is due to upregulation of nitric oxide and interferon-gamma production by tumor-associated macrophages. Cancer Sci 2009, 100(11):2160-6. 10.1111/j.1349-7006.2009.01296.x, 19694752.
33. Yamaguchi H, Pixley F, Condeelis J. Invadopodia and podosomes in tumor invasion. Eur J Cell Biol 2006, 85(3-4):213-8. 10.1016/j.ejcb.2005.10.004, 16546563.
34. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124(2):263-6. 10.1016/j.cell.2006.01.007, 16439202.
35. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 2004, 64(19):7022-9. 10.1158/0008-5472.CAN-04-1449, 15466195.
36. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008, 84(3):623-30. 10.1189/jlb.1107762, 2516896, 18467655.
37. Wang W, Goswami S, Sahai E, Wyckoff JB, Segall JE, Condeelis JS. Tumor cells caught in the act of invading: their strategy for enhanced cell motility. Trends Cell Biol 2005, 15(3):138-45. 10.1016/j.tcb.2005.01.003, 15752977.
38. Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 2004, 25(8):1543-9. 10.1093/carcin/bgh146, 15044327.
39. Ingman WV, Wyckoff J, Gouon-Evans V, Condeelis J, Pollard JW. Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland. Dev Dyn 2006, 235(12):3222-9. 10.1002/dvdy.20972, 17029292.
40. Oosterling SJ, van der Bij GJ, Meijer GA, Tuk CW, van Garderen E, van Rooijen N, et al. Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol 2005, 207(2):147-55. 10.1002/path.1830, 16104052.
41. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4(1):71-8. 10.1038/nrc1256, 14708027.
42. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001, 61(2):577-81.
43. Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 2001, 3(6):459-68. 10.1038/sj.neo.7900190, 1506562, 11774028.
44. Lee AH, Happerfield LC, Bobrow LG, Millis RR. Angiogenesis and inflammation in invasive carcinoma of the breast. J Clin Pathol 1997, 50(8):669-73. 10.1136/jcp.50.8.669, 500114, 9301551.
45. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996, 97(12):2692-6. 10.1172/JCI118722, 507360, 8675678.
46. Stresing V, Daubiné F, Benzaid I, Mönkkönen H, Clézardin P. Bisphosphonates in cancer therapy. Cancer Letters 2007, 257(1):16-35. 10.1016/j.canlet.2007.07.007, 17697748.
47. Winter MC, Coleman RE. Bisphosphonates in breast cancer: teaching an old dog new tricks. Curr Opin Oncol 2009, 21(6):499-506. 10.1097/CCO.0b013e328331c794, 19730102.
48. Stern PH. Antiresorptive agents and osteoclast apoptosis. Journal of Cellular Biochemistry 2007, 101(5):1087-96. 10.1002/jcb.21311, 17407157.
49. Moreau MF, Guillet C, Massin P, Chevalier S, Gascan H, Baslé MF, et al. Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochemical Pharmacology 2007, 73(5):718-23. 10.1016/j.bcp.2006.09.031, 17157266.
50. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ. Nitrogen-Containing Biphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins. Including Ras. 13 1998, 11(4).
51. Mönkkönen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsäläinen J, et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. British Journal of Pharmacology 2006, 147:437-45. 10.1038/sj.bjp.0706628, 1616989, 16402039.
52. Green JR. Bisphosphonates in cancer therapy. Current Opinion in Oncology 2002, 14(6):609-15. 10.1097/00001622-200211000-00004, 12409650.
53. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296(2):235-42.
54. Arantes HP, Silva AG, Lazaretti-Castro M. Bisphosphonates in the treatment of metabolic bone diseases. Arq Bras Endocrinol Metabol 2010, 54(2):206-12. 10.1590/S0004-27302010000200017, 20485910.
55. Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007, 86(11):1022-33. 10.1177/154405910708601102, 17959891.
56. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88(12 Suppl):2961-78.
57. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999, 25(1):97-106. 10.1016/S8756-3282(99)00116-7, 10423031.
58. Santini D, Schiavon G, Angeletti S, Vincenzi B, Gasparro S, Grilli C, et al. Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs?. Recent Pat Anticancer Drug Discov 2006, 1(3):383-96. 10.2174/157489206778776989, 18221048.
59. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2(8):584-93. 10.1038/nrc867, 12154351.
60. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997, 57(18):3890-4.
61. Van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996, 98(3):698-705. 10.1172/JCI118841, 507479, 8698861.
62. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000, 60(11):2949-54.
63. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004, 10(13):4559-67. 10.1158/1078-0432.CCR-03-0325, 15240548.
64. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000, 15(11):2211-21. 10.1359/jbmr.2000.15.11.2211, 11092402.
65. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000, 82(8):1459-68. 2363380, 10780527.
66. Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002, 86(9):1479-86. 10.1038/sj.bjc.6600297, 2375368, 11986784.
67. Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006, 69(5):1624-32. 10.1124/mol.105.020776, 16501031.
68. Rogers MJ, Chilton KM, Coxon FP, Lawry J, Smith MO, Suri S, et al. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. Journal of Bone and Mineral Research 1996, 11(10):1482-91.
69. Cecchini MG, Felix R, Fleisch H, Cooper PH. Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. Journal of Bone and Mineral Research 1987, 2(2):135-42.
70. Cecchini MG, Fleisch H. Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. Journal of Bone and Mineral Research 1990, 5(10):1019-27.
71. Valleala H, Hanemaaijer R, Mandelin J, Salminen A, Teronen O, Mönkkönen J, et al. Regulation of MMP-9 (gelatinase B) in activated human monocyte/macrophages by two different types of bisphosphonates. Life Sciences 2003, 73(19):2413-20. 10.1016/S0024-3205(03)00657-X, 12954450.
72. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004, 114(5):623-33. 514591, 15343380.
73. Luckman SP, Coxon FP, Ebetino FH, Russell RGG, Rogers MJ. Heterocycle-Containing Bisphosphonates Cause Apoptosis and Inhibit Bone Resorption by Preventing Protein Prenylation: Evidence from Structure-Activity Relationships in J774 Macrophages. Journal of Bone and Mineral Research 1998, 13(11):1668-78. 10.1359/jbmr.1998.13.11.1668, 9797474.
74. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001, 13(2):85-94. 10.1016/S0898-6568(00)00149-2, 11257452.
75. Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat 2010, 123(1):39-49. 10.1007/s10549-009-0622-8, 20711669.
76. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008, 222:162-79. 10.1111/j.1600-065X.2008.00602.x, 18364001.
77. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9(3):162-74. 10.1038/nri2506, 2828349, 19197294.
78. Tsagozis P, Eriksson F, Pisa P. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunol Immunother 2008, 57(10):1451-9. 10.1007/s00262-008-0482-9, 18297280.
79. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002, 8(5):1080-4.
80. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003, 9(8):2893-7.
81. Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005, 25(3):144-51. 10.1089/jir.2005.25.144, 15767788.
82. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007, 13(15 Pt 1):4482-6.
83. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010, 14(12):2803-15. 10.1111/j.1582-4934.2009.00926.x, 19818098.
84. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol England 2002, 23(11):549-55.
85. Hiraoka K, Zenmyo M, Watari K, Iguchi H, Fotovati A, Kimura YN, et al. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci 2008, 99(8):1595-602. 10.1111/j.1349-7006.2008.00880.x, 18754872.
86. Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol 2007, 127(8):2031-41. 10.1038/sj.jid.5700827, 17460736.
87. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 2006, 95(3):272-81. 10.1038/sj.bjc.6603240, 2360657, 16832418.
88. Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, Xu HX, et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 2010, 16(13):3420-30. 10.1158/1078-0432.CCR-09-2904, 20570927.
89. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Hegmans JP, et al. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br J Cancer 2010, 103(5):629-41. 10.1038/sj.bjc.6605814, 2938257, 20664588.
90. Marra M, Abbruzzese A, Addeo R, Del Prete S, Tassone P, Tonini G, et al. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. Curr Cancer Drug Targets 2009, 9(7):791-800. 10.2174/156800909789760285, 20025567.
91. Marra M, Salzano G, Leonetti C, Porru M, Franco R, Zappavigna S, et al. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv 2011,
92. Salzano G, Marra M, Porru M, Zappavigna S, Abbruzzese A, La Rotonda MI, et al. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. Int J Pharm 2011, 403(1-2):292-7. 10.1016/j.ijpharm.2010.10.046, 21055454.
93. Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S, et al. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine 2011,
94. Heymann D, Ory B, Gouin F, Green JR, Redini F. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med 2004, 10(7):337-43. 10.1016/j.molmed.2004.05.007, 15242682.
95. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000, 18(6):1378-91.
96. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21(21):4042-57. 10.1200/JCO.2003.08.017, 12963702.
97. Frith JC, Rogers MJ. Antagonistic Effects of Different Classes of Bisphosphonates in Osteoclasts and Macrophages In Vitro. J Bone Miner Res 2003, 18(2):204-12. 10.1359/jbmr.2003.18.2.204, 12568397.
98. Monkkonen H, Rogers MJ, Makkonen N, Niva S, Auriola S, Monkkonen J. The cellular uptake and metabolism of clodronate in RAW 264 macrophages. Pharm Res 2001, 18(11):1550-5. 10.1023/A:1013026313647, 11758762.